mRNA 1647
Alternative Names: CMV vaccine - Moderna Therapeutics; Cytomegalovirus vaccine - Moderna Therapeutics; mRNA-1647Latest Information Update: 13 Feb 2026
At a glance
- Originator Moderna Therapeutics
- Class Cytomegalovirus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 19 Jan 2026 Moderna Therapeutics completes a phase II long-term extension trial in Cytomegalovirus infections (Prevention) in USA (IM) (NCT04975893)
- 06 Dec 2025 Immunogenicity data from phase I trial in healthy volunteers presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-2025)
- 20 Nov 2025 Discontinued - Phase-I/II for Cytomegalovirus infections (In adolescents, In children, Prevention, In adults) in United Kingdom (IM) due to strategic prioritization